PT - JOURNAL ARTICLE AU - Shackley, D AU - Gray, S AU - Penney, S AU - Galligan-Dawson, L AU - Howle, F AU - Arya, S AU - Hunter, J AU - Andrews, F AU - Wasson, C AU - Luckas, M AU - Ryan, B AU - Eddleston, J AU - Brookes, C AU - Harrison, C TI - The Safety of Contemporary Planned Cancer Surgery During the COVID-19 Pandemic AID - 10.1101/2020.10.19.20207803 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.19.20207803 4099 - http://medrxiv.org/content/early/2020/10/20/2020.10.19.20207803.short 4100 - http://medrxiv.org/content/early/2020/10/20/2020.10.19.20207803.full AB - Introduction The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 has put an unprecedented burden on global healthcare, including detrimental implications for the volume and provision of surgical services. The aim of this audit was to assess if the planned surgical cancer care (both diagnostic for possible cancer, and treatment of known cancer) during this period of widespread community and hospital based COVID-19 infection resulted in patients acquiring symptomatic COVID-19 as a consequence of their surgical admission, and if so, what the impact on patients was.Methods A prospective audit of all patients undergoing elective cancer surgery in Greater Manchester operated on between 01/05/2020 and 31/06/2020 was undertaken after the introduction of specific peri operative COVID safety measures across Greater Manchester cancer surgical cells. The COVID related outcomes for all cancer patients operated on in Greater Manchester were recorded.Results Of the 1501 patients undergoing surgery, one (<0.1%) was diagnosed with COVID-19 in hospital within 14 days of surgery. This patient did not require admission to critical care due to post-operative COVID-19 diagnosis, and there was no associated mortality related to post-operative COVID-19 infection.Conclusion The use of peri operative COVID-19 infection prevention strategies has allowed for the safe continuation of elective cancer surgery during this pandemic in all surgical units, without significant additional COVID-19 related morbidity or mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding through Greater Manchester Cancer servicesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted for this study from each of the 10 trusts committing patients to this studies' ethic review board. Namely ethical approval was sought from the ethics review boards and quality improvement projects from The Northern Care Alliance NHS Foundaiton Trust, Manchester University NHS Foundation Trust, Wigan, Wrightington and Leigh Teaching Hospitals NHS Foundation Trust, East Cheshire NHS Trust, Bolton NHS Foundation Trust, Stockport NHS Foundation Trust, Mid Cheshire Hospitals NHS Foundation Trust ,Tameside Hospital NHS Foundation Trust and the Christie NHS Foundation Trust. This was organised through the Greater Manchester Cancer group. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data available to public